Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of
Debio 0123 in combination with carboplatin in participants with advanced solid tumors that
recurred or progressed after prior platinum based therapy and for which no standard therapy
of proven benefit is available.